GLPwatch
Papers (10404)
Page 98 of 174, ranked by citation count.
- Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
- [Liraglutide promotes proliferation and migration of cardiac microvascular endothelial cells through PI3K/Akt and MAPK/ERK signaling pathways].
- Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet.
- Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
- Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
- Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.
- Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
- GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.
- EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.
- Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery.
- Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet.
- Evaluation of gastric content in fasting patient during semaglutide use: an observational study.
- Glycosylation Improves the Proteolytic Stability of Exenatide.
- Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
- Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.
- Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.
- Liraglutide protects Rin-m5f β cells by reducing procoagulant tissue factor activity and apoptosis prompted by microparticles under conditions mimicking Instant Blood-Mediated Inflammatory Reaction.
- SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
- Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells.
- Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.
- Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.
- Controlling the uncontrolled variation in the diet induced obese mouse by microbiomic characterization.
- Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch<sup>®</sup> among self-injection-naïve patients with type 2 diabetes mellitus in Japan.
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.
- Hot weight loss drugs tested against addiction.
- The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide.
- The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study.
- Liraglutide promotes UCP1 expression and lipolysis of adipocytes by promoting the secretion of irisin from skeletal muscle cells.
- Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
- Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
- Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
- The Use of Semaglutide in Patients Undergoing Lumbar Fusion Does not Increase 90-Day Medical or 1-Year Implant Complications.
- Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes.
- Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
- Effect of GLP-1 receptor agonists on body composition.
- Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
- GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD.
- GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.
- The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.
- Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.
- Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.
- The effectiveness and value of tirzepatide for type 2 diabetes mellitus.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
- Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro.
- Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
- A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.
- Exendin-4 protects murine pancreatic β-cells from free fatty acid-induced apoptosis through PI-3K signaling.
- Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Implications of immortal person-time when outcomes are nonfatal.
- Pyoderma gangrenosum associated with dulaglutide therapy.
- Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
- Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats.
- Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
- GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation.
- Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action.
- [Exenatide stimulated solute-free water excretion by human kidney].
- Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.
- Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models.